Pharmacy Benefits & Drug Pricing
Expert articles and analysis related to pharmacy benefits & drug pricing.
AI Summary — Last 24 Hours
Synthesis:
In the past 24 hours, CMS has issued a proposed rule to require fully electronic prior authorization for prescription drugs across both medical and pharmacy benefits, aiming to phase out traditional workflows like faxes and payer portals. This move has significant implications for value-based care stakeholders—including ACOs and managed care organizations—by promising reduced administrative burden, faster treatment timelines, and potentially lower total cost of care, but also raising challenges around IT system integration and real-time data exchange. For population health and payment model innovators, the regulation could accelerate the shift to seamless, tech-enabled medication management to support clinical outcomes and financial targets. For details, see CMS proposes electronic prior authorization for drugs and New Prior Authorization Proposals: Implications for Prescription Drug Access.
Related Articles
The 340B Drug Pricing Program Is A Hidden Tax Expenditure
The 340B Drug Pricing Program Is A Hidden Tax Expenditure  Health Affairs
STAT+: Pharmalittle: We’re reading about a Trump deal with Regeneron, reclassifying medical marijuana, and more
President Trump heralded a drug-pricing agreement with Regeneron, closing the last of 17 deals sought by the White House
340B is a Hidden Tax Expenditure
340B is a Hidden Tax Expenditure  Healthcare Economist
White House announces MFN agreement with drug manufacturer Regeneron
White House announces MFN agreement with drug manufacturer Regeneron  American Hospital Association
STAT+: Sanofi MS drug gets positive review in Europe following FDA
A multiple sclerosis drug from Sanofi that was rejected late last year by the FDA found a warmer reception in Europe.
Bridging the Gap: The Future of GLP-1 Coverage in Part D
FDA fast-tracks the development of psychedelic medications following president’s executive order
FDA fast-tracks the development of psychedelic medications following president’s executive order  American Hospital Association
STAT+: FDA to speed up review of three psychedelics as mental health treatments
Trump's embrace of psychedelics and cannabis is shaking up the GOP’s relationship with mind-altering substances.
New Prior Authorization Proposals: Implications for Prescription Drug Access
New Prior Authorization Proposals: Implications for Prescription Drug Access  Health Affairs
STAT+: A biotech VC on what Eli Lilly saw in a struggling cancer startup for $3.2B
What did Eli Lilly see in a struggling biotech startup that made the pharma giant want to pay billions for it? Bryan Roberts has some answers.